Heritas Capital’s portfolio company Holmusk raised additional US$30m investment funding from Veradigm to power behavioural health real world evidence-based insights and solutions
Congratulations to Holmusk for raising additional US$30m funding from Veradigm Inc.. This funding builds on the Series B round completed earlier this year also led by Veradigm and participated by Heritas Capital alongside Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.
This strategic collaboration draws on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward. In this new phase of collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a leading source for real-world data that shows how behavioral health care is delivered. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts.
Read more on the strategic investment in the press release.